SOPHiA GENETICS SA [●] Ordinary Shares Underwriting AgreementUnderwriting Agreement • July 19th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] ordinary shares, par value CHF 0.05 per share (the “Ordinary Shares”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to [●] additional Ordinary Shares (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.”
SOPHiA GENETICS SA SALES AGREEMENTSales Agreement • August 8th, 2023 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
AMENDMENT NO.1 TO A MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • July 2nd, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • Delaware
WHEREAS The Parties entered into an “Amended and Restated Manufacturing and Supply Agreement” on October 9th, 2018 (the “Main Agreement”);
EXCLUSIVE LICENCE OF PATENTS AND RESULTSSOPHiA GENETICS SA • May 24th, 2021 • Biological products, (no disgnostic substances)
BETWEEN THE UNDERSIGNED, SOPHIA GENETICS SA, a company duly incorporated in accordance with the laws of Switzerland, under registration number CH-550.1.086.569-3 in the Commercial Register of the Canton of Vaud, domiciled at Rue du Centre 172, 1025 St-Sulpice, Switzerland, represented by [**], duly authorised for this purpose and hereinafter referred to as the “Company”;
INDEMNITY AGREEMENT made as of [date], 2021 betweenIndemnity Agreement • July 2nd, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances)
AMENDMENT No. 1 TO THE SOPHIA GENETICS SA AGREEMENT dated January 19, 2018 (the “Amendment”)Sa Agreement • May 24th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances)
Sophia Genetics SA, Rue du Centre 172, CH-1025 Saint-Sulpice, Switzerland a corporation organized under the laws of the Switzerland (“Sophia Genetics SA”);
SHARE PURCHASE AGREEMENT by and between SOPHiA GENETICS SA and The Investors Named Herein Dated as of July 17, 2021Share Purchase Agreement • July 19th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SHARE PURCHASE AGREEMENT, dated as of July 17, 2021 (this “Agreement”), by and between SOPHiA GENETICS SA, a société anonyme domiciled in Saint-Sulpice, Canton of Vaud, Switzerland, and organized under the laws of Switzerland (the “Company”), and the investors named on Schedule I hereto (each, an “Investor”, and collectively, the “Investors”).
SOFTWARE SUB-LICENCE AGREEMENT TO SOPHIA GENETICSSoftware Sub-Licence Agreement • May 24th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances)
BETWEEN THE UNDERSIGNED, SATT AQUITAINE, Aquitaine Science Transfert, SAS, SIRET number [**], whose head office is located at [**], hereinafter referred to as “SATT Aquitaine” and SOPHiA GENETICS SA, a company duly incorporated under the laws of Switzerland, bearing the registration number CH-550.1.086.569-3 in the Commercial Register of the Canton of Vaud, domiciled at Rue du Centre 172, 1025 St-Sulpice, Switzerland, represented by [**], duly authorised for this purpose, hereinafter referred to as “SOPHiA GENETICS”.
AGREEMENT FOR THE CO-MARKETING OF PRODUCTS AND SERVICESProducts and Services • May 24th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
WHEREAS SOPHiA seeks to develop algorithms to analyse data associated with Agilent gene panels and sell access to its platform to interpret this data;
SUPPLY AGREEMENTSupply Agreement • March 15th, 2022 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • England and Wales
This Supply Agreement (this “Agreement”) is made as of the 4th day of January, 2019 (the “Effective Date”) by and between New England Biolabs, Inc., a Massachusetts corporation, having a principal place of business at [**] (“NEB”), and Sophia Genetics SA, a Swiss corporation, having its principal place of business at Rue du Centre 172, 1025 St-Sulpice, Switzerland (“Purchaser”). NEB and Purchaser may each be referred to individually as a “Party”, or together as the “Parties”.
AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT “Lockdown NGS Panels”Manufacturing and Supply Agreement • May 24th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • England
OEM SUPPLY AGREEMENT (the “Agreement”)Oem Supply Agreement • May 24th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances)
WHEREAS QIAGEN is skilled and experienced in the development, manufacture and marketing of certain amplification technologies including library amplification kits applied for Next Generation Sequencing Technologies for the research and diagnostic markets;
MASTER ALLIANCE AGREEMENTMaster Alliance Agreement • March 15th, 2022 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SUPPLY AGREEMENT (the “Agreement”)Supply Agreement • May 24th, 2021 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
TWIST BIOSCIENCE CORPORATION, a company constituted under the laws of the State of Delaware, USA, having a place of business at [**] (hereinafter to be referred to as the “Twist”),
